Clinical trial
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
NCT00070941 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00070941 |
|---|---|
| Title | SAM-e for the Treatment of Depression in Patients With Parkinson's Disease |
| Official title | SAM-e Treatment of Depression in Parkinson's Disease. |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Center for Complementary and Integrative Health (NCCIH) NIH Office of Dietary Supplements (ODS) |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease, Depression |
| Intervention type | Drug |
| Interventions | SAM-e, oral escitalopram, placebo |
| Enrollment | 29 |
| Start date | Jul 1, 2003 |
| Primary completion | Jun 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Oct 13, 2003 |
| Last update posted | Jul 13, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: